Ovid Therapeutics Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 0/6

Ovid TherapeuticsDie Gewinne des Unternehmens sind mit einer durchschnittlichen jährlichen Rate von -4.4% zurückgegangen, während in der Branche Biotechs die Gewinne wachsen. Die Umsätze sind rückläufig mit einer durchschnittlichen Rate von 27.6% pro Jahr.

Wichtige Informationen

-4.4%

Wachstumsrate der Gewinne

7.0%

EPS-Wachstumsrate

Biotechs Wachstum der Industrie	17.0%
Wachstumsrate der Einnahmen	-27.6%
Eigenkapitalrendite	-42.6%
Netto-Marge	-5,145.2%
Letzte Ertragsaktualisierung	30 Sep 2024

Jüngste Aktualisierungen vergangener Leistungen

Recent updates

Ovid Therapeutics: Data Readouts For Rare Epileptic Indications Late 2024

Apr 09

We Think Ovid Therapeutics (NASDAQ:OVID) Can Afford To Drive Business Growth

Nov 10

Companies Like Ovid Therapeutics (NASDAQ:OVID) Are In A Position To Invest In Growth

Jun 27

Here's Why We're Watching Ovid Therapeutics' (NASDAQ:OVID) Cash Burn Situation

Mar 13

Is Ovid Therapeutics (NASDAQ:OVID) In A Good Position To Deliver On Growth Plans?

Sep 09

Ovid Therapeutics GAAP EPS of -$0.21 beats by $0.04

Aug 09

We Think Ovid Therapeutics (NASDAQ:OVID) Needs To Drive Business Growth Carefully

Jun 09

Ovid Therapeutics: Good Entry Point For Investors

Jun 18

Ovid Therapeutics appoints Jeff Rona as CFO

Jun 04

Ovid Therapeutics Inc. (NASDAQ:OVID) Could Be Less Than A Year Away From Profitability

Apr 16

Analysts Just Made A Captivating Upgrade To Their Ovid Therapeutics Inc. (NASDAQ:OVID) Forecasts

Mar 20

Ovid Therapeutics Inc. (NASDAQ:OVID) Just Reported Full-Year Earnings And Analysts Are Lifting Their Estimates

Mar 18

We're Keeping An Eye On Ovid Therapeutics' (NASDAQ:OVID) Cash Burn Rate

Mar 01

Is Ovid Therapeutics Inc.'s (NASDAQ:OVID) Shareholder Ownership Skewed Towards Insiders?

Jan 25

Revisiting Ovid Therapeutics

Jan 14

Would Shareholders Who Purchased Ovid Therapeutics' (NASDAQ:OVID) Stock Three Years Be Happy With The Share price Today?

Dec 21

Ovid Therapeutics misses goal in Angelman syndrome treatment

Dec 01

Aufschlüsselung der Einnahmen und Ausgaben

Wie Ovid Therapeutics Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.

Gewinn- und Umsatzhistorie

NasdaqGS:OVID Einnahmen, Ausgaben und Erträge (USD Millions)
Datum	Einnahmen	Umsatz	Allgemeine und Verwaltungskosten	F&E-Ausgaben
30 Sep 24	1	-33	25	41
30 Jun 24	1	-30	28	39
31 Mar 24	0	-51	30	32
31 Dec 23	0	-52	31	29
30 Sep 23	0	-49	31	24
30 Jun 23	0	-49	32	25
31 Mar 23	0	-51	31	23
31 Dec 22	2	-54	32	25
30 Sep 22	1	-68	33	37
30 Jun 22	1	-66	32	36
31 Mar 22	1	-67	32	39
31 Dec 21	208	120	37	47
30 Sep 21	214	123	39	46
30 Jun 21	221	117	40	57
31 Mar 21	221	110	41	65
31 Dec 20	13	-81	31	63
30 Sep 20	7	-76	25	59
30 Jun 20	0	-76	23	54
31 Mar 20	0	-67	20	47
31 Dec 19	0	-60	19	42
30 Sep 19	0	-56	19	39
30 Jun 19	0	-53	18	36
31 Mar 19	0	-53	19	35
31 Dec 18	0	-52	19	34
30 Sep 18	0	-50	19	32
30 Jun 18	0	-46	18	29
31 Mar 18	0	-44	17	27
31 Dec 17	0	-65	15	50
30 Sep 17	0	-61	14	47
30 Jun 17	0	-58	14	44
31 Mar 17	0	-53	13	40
31 Dec 16	0	-22	13	10
30 Sep 16	0	-18	12	2
31 Dec 15	0	-13	7	7

Qualität der Erträge: OVID ist derzeit unrentabel.

Wachsende Gewinnspanne: OVID ist derzeit unrentabel.

Analyse von freiem Cashflow und Gewinn

Analyse des Gewinnwachstums in der Vergangenheit

Ergebnisentwicklung: OVID ist unrentabel, und die Verluste haben in den letzten 5 Jahren mit einer Rate von 4.4% pro Jahr zugenommen.

Beschleunigtes Wachstum: Das Gewinnwachstum des letzten Jahres kann nicht mit dem 5-Jahres-Durchschnitt von OVID verglichen werden, da das Unternehmen derzeit nicht profitabel ist.

Erträge im Vergleich zur Industrie: OVID ist unrentabel, was einen Vergleich des Gewinnwachstums des letzten Jahres mit der Branche Biotechs (16.6%) erschwert.

Eigenkapitalrendite

Hohe Eigenkapitalrendite: OVID hat eine negative Eigenkapitalrendite (-42.6%), da es derzeit unrentabel ist.

Ovid Therapeutics Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen vergangener Leistungen

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Full year 2023 earnings: EPS and revenues miss analyst expectations

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Third quarter 2022 earnings released: US$0.17 loss per share (vs US$0.17 loss in 3Q 2021)

Recent updates

High number of new and inexperienced directors

Consensus revenue estimates increase by 45%, EPS downgraded

New major risk - Financial position

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

High number of new and inexperienced directors

Ovid Therapeutics Appoints Dr. Amanda Banks, as Chief Development Officer

Ovid Therapeutics Inc. Expands Scientific Advisory Board

Ovid Therapeutics Inc. Announces That eNeuro Publishes Findings on the Anti-Convulsant Properties of OV329 and Its Potential Effectiveness in Treatment-Resistant Seizures

Ovid Therapeutics Inc.(NasdaqGS:OVID) dropped from Russell Small Cap Comp Value Index

Ovid Therapeutics Inc. and Graviton Bioscience Corporation Announce Topline Data from A Phase 1 Clinical Trial Studying OV888/GV101 Capsule

Consensus revenue estimates decrease by 87%, EPS upgraded

Consensus revenue estimates fall by 80%

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Ovid Therapeutics Inc., Annual General Meeting, Jun 06, 2024

Ovid Therapeutics: Data Readouts For Rare Epileptic Indications Late 2024

President recently bought US$50k worth of stock

Full year 2023 earnings: EPS and revenues miss analyst expectations

High number of new and inexperienced directors

Consensus revenue estimates increase by 1,902%

We Think Ovid Therapeutics (NASDAQ:OVID) Can Afford To Drive Business Growth

Consensus revenue estimates increase by 51%

Price target increased by 20% to US$6.00

Consensus revenue estimates increase by 48%

Ovid Therapeutics Inc. Announces Changes to Its Board

Companies Like Ovid Therapeutics (NASDAQ:OVID) Are In A Position To Invest In Growth

Consensus revenue estimates increase by 14%

Price target increased by 7.1% to US$5.00

Consensus revenue estimates increase by 60%, EPS downgraded

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Here's Why We're Watching Ovid Therapeutics' (NASDAQ:OVID) Cash Burn Situation

Ovid Therapeutics Expands Epilepsy Development Expertise with New Appointments

Ovid Therapeutics Doses Healthy Volunteers with OV329 in Phase 1 Trial

High number of new and inexperienced directors

Third quarter 2022 earnings released: US$0.17 loss per share (vs US$0.17 loss in 3Q 2021)

Is Ovid Therapeutics (NASDAQ:OVID) In A Good Position To Deliver On Growth Plans?

Consensus forecasts updated

Second quarter 2022 earnings released: US$0.21 loss per share (vs US$0.23 loss in 2Q 2021)

Ovid Therapeutics GAAP EPS of -$0.21 beats by $0.04

We Think Ovid Therapeutics (NASDAQ:OVID) Needs To Drive Business Growth Carefully

Price target decreased to US$4.70

Ovid Therapeutics Inc., Annual General Meeting, Jun 09, 2022

Price target increased to US$5.50

High number of new and inexperienced directors

Full year 2021 earnings: EPS misses analyst expectations

Price target increased to US$5.50

President & Chief Medical Officer notifies of intention to sell stock

Ovid Therapeutics Inc.(NasdaqGS:OVID) dropped from Russell 3000E Index

Treasurer & Corporate Controller Timothy Daly has left the company

Ovid Therapeutics: Good Entry Point For Investors

Ovid Therapeutics appoints Jeff Rona as CFO

Price target decreased to US$4.88

Investor sentiment improved over the past week

Price target decreased to US$5.40

Ovid Therapeutics Inc. (NASDAQ:OVID) Could Be Less Than A Year Away From Profitability

Analysts Just Made A Captivating Upgrade To Their Ovid Therapeutics Inc. (NASDAQ:OVID) Forecasts

Ovid Therapeutics Inc. (NASDAQ:OVID) Just Reported Full-Year Earnings And Analysts Are Lifting Their Estimates

Takeda Pharmaceutical Company Limited and Ovid Therapeutics Inc. to Develop and Commercialize Soticlestat for the Treatment of Children and Adults with Dravet Syndrome and Lennox-Gastaut Syndrome

New 90-day high: US$4.04

We're Keeping An Eye On Ovid Therapeutics' (NASDAQ:OVID) Cash Burn Rate

Is Ovid Therapeutics Inc.'s (NASDAQ:OVID) Shareholder Ownership Skewed Towards Insiders?

Revisiting Ovid Therapeutics

New 90-day low: US$2.42

Would Shareholders Who Purchased Ovid Therapeutics' (NASDAQ:OVID) Stock Three Years Be Happy With The Share price Today?

Analysts increase revenue estimates to US$11.1m

Ovid Therapeutics Inc. Announces Phase 3 NEPTUNE Clinical Trial of OV101 for the Treatment of Angelman Syndrome Did Not Meet Primary Endpoint

Ovid Therapeutics misses goal in Angelman syndrome treatment

New 90-day high: US$6.84

Price target raised to US$14.67